ATP25 Antibody

What is ATP25 and why is it significant in mitochondrial research?

ATP25 (identified from reading frame YMR098C on chromosome XIII in yeast) is a nuclear gene required for expression of Atp9p (subunit 9) of the Saccharomyces cerevisiae mitochondrial proton translocating ATPase. Its significance lies in its crucial role in maintaining stability of ATP9 mRNA and enabling proper assembly of functional F₀ in the mitochondrial ATPase complex . Mutations in ATP25 cause a deficit of ATP9 mRNA and its translation product, preventing assembly of functional F₀ while not affecting other mitochondrial gene products . Understanding ATP25 function provides insights into nuclear-mitochondrial communication and the regulation of energy production in eukaryotic cells.

How is ATP25 protein processed in mitochondria?

ATP25 protein undergoes significant post-translational processing in vivo. The primary translation product has a predicted mass of 70 kDa, but Western blot analysis reveals that it is cleaved after residue 292 (specifically after Tyr292) to yield a 35-kDa C-terminal polypeptide . This processing appears to be physiological rather than an isolation artifact, as confirmed through multiple experimental approaches including the use of protease inhibitors and gradient purification of mitochondria . The C-terminal half of ATP25 is associated with the inner mitochondrial membrane and faces the matrix side, consistent with its role in stabilizing ATP9 mRNA .

What detection methods are suitable for ATP25 protein in experimental settings?

Based on experimental approaches described in the literature, several methods have proven effective for ATP25 detection:

• Western blotting: Using antibodies directed against either the C-terminal half of the protein or epitope tags (HA or polyhistidine) added to the C-terminus .

• Protein localization studies: Combining proteinase K treatment of intact and hypotonically lysed mitochondria with Western blotting to determine submitochondrial localization .

• Blue Native PAGE (BN-PAGE): For analyzing protein complexes containing ATP25 or studying the effects of ATP25 mutations on ATPase complex assembly .

• Affinity purification: Using nickel-NTA acid columns for polyhistidine-tagged versions of the protein, followed by SDS-PAGE for further purification .

How can I verify the specificity of an ATP25 antibody in research applications?

Verifying ATP25 antibody specificity requires multiple complementary approaches:

• Genetic controls: Compare antibody reactivity in wild-type cells versus ATP25 null mutants. The absence of a specific signal in the null mutant confirms antibody specificity as demonstrated in Western blot experiments described in the literature .

• Epitope tagging validation: Express ATP25 with a C-terminal tag (HA or polyhistidine) and confirm that both the tag-specific antibody and the ATP25-specific antibody recognize the same protein band(s) .

• N-terminal sequencing: For definitive validation, purify the protein recognized by the antibody and perform N-terminal sequencing to confirm its identity. This approach confirmed the cleavage site of ATP25 (after Tyr292) in published research .

• Cross-reactivity assessment: Test the antibody against related proteins or in systems where ATP25 is overexpressed versus normally expressed to assess potential cross-reactivity with other proteins .

What experimental approaches can resolve the dual function of ATP25 N-terminal and C-terminal domains?

Research has revealed that both halves of ATP25 are required for full respiratory function, suggesting distinct roles for each domain . To investigate these functions:

• Complementation analysis: Transform ATP25 null mutants with constructs expressing either the N-terminal half, C-terminal half, or both halves together. Assess respiratory growth and cytochrome content to determine functional contributions of each domain .

• mRNA stability assays: The C-terminal half of ATP25 is sufficient to stabilize ATP9 mRNA. Use Northern blotting to assess ATP9 transcript levels in strains expressing only the C-terminal domain .

• Protein complex assembly analysis: The N-terminal half appears involved in Atp9p oligomerization. Use blue native PAGE and antibodies against ATPase subunits to analyze complex formation in strains expressing only the C-terminal domain of ATP25 .

• In vivo labeling: Label mitochondrial translation products to assess the synthesis of Atp9p and other mitochondrially encoded proteins in strains with mutations in different domains of ATP25 .

How can I differentiate between ATP25's roles in ATP9 mRNA stability versus protein assembly?

This represents a challenging aspect of ATP25 research, requiring careful experimental design:

• Temperature-sensitive mutants: Utilize temperature-sensitive ATP25 mutants to observe time-dependent effects on ATP9 mRNA levels and protein synthesis after shifting to non-permissive temperatures. This approach revealed that both mRNA disappearance and protein synthesis arrest occur after approximately 4 hours at restrictive temperature .

• Domain-specific manipulations: Express only the C-terminal domain of ATP25, which is sufficient for ATP9 mRNA stability but not for full respiratory function. This separation of functions allows investigation of assembly-specific defects in the presence of normal mRNA levels .

• Analysis of assembly intermediates: Examine the formation of subcomplexes of the ATP synthase using blue native PAGE and Western blotting with antibodies against different subunits in strains with specific ATP25 domain mutations .

• Oligomycin sensitivity assays: The sensitivity of ATPase activity to oligomycin provides a reliable indicator of proper F₀ assembly. As shown in published data, wild-type cells exhibit high oligomycin sensitivity (76.9-88.5% inhibition), while ATP25 mutants grown at restrictive temperature show minimal sensitivity (2.1% inhibition) .

What are best practices for subcellular fractionation when studying ATP25?

For accurate localization and functional studies of ATP25, proper subcellular fractionation is crucial:

• Gradient purification: Further purify mitochondria on Nycodenz gradients to remove possible lysosomal contamination that might contribute to artifactual protein degradation .

• Protease inhibition: Include protease inhibitors such as phenylmethylsulfonyl fluoride (PMSF) at all stages of mitochondrial isolation to prevent unwanted proteolysis .

• Submitochondrial localization: Combine proteinase K treatment of intact mitochondria and mitoplasts (mitochondria with the outer membrane removed by hypotonic treatment) with Western blotting to determine precise submitochondrial localization .

• Verification of fraction purity: Use established markers for different submitochondrial compartments, such as cytochrome b₂ for the intermembrane space and α-ketoglutarate dehydrogenase for the matrix, to confirm the integrity of fractionation procedures .

What analytical techniques can resolve the multiple forms of ATP25 protein?

The different forms of ATP25 (full-length ~70 kDa, processed ~60 kDa, and C-terminal ~35 kDa forms) present analytical challenges:

• Optimized SDS-PAGE conditions: Use gradient gels (e.g., 10-15%) to adequately separate both the full-length and processed forms of ATP25 .

• Epitope tagging strategies: Add tags (HA or polyhistidine) to either the N-terminus or C-terminus to track specific portions of the protein through processing events .

• Two-dimensional gel electrophoresis: Combine isoelectric focusing with SDS-PAGE to resolve forms that may have similar molecular weights but different charge characteristics.

• Mass spectrometry: For definitive characterization of the different ATP25 forms, employ mass spectrometry following affinity purification .

How can I interpret contradictory results when analyzing ATP25 function?

Research on ATP25 function can produce seemingly contradictory results due to its dual role in mRNA stability and protein assembly:

What controls are essential when using ATP25 antibodies in research?

Based on established research practices, the following controls are essential:

• Genetic knockout controls: Include ATP25 null mutants to confirm signal specificity .

• Antibody validation controls: For commercial antibodies, validate specificity in your experimental system using overexpression and/or epitope-tagged versions of ATP25 .

• Cross-reactivity assessment: The polyclonal antibody against the C-terminal half of ATP25 cross-reacted with multiple proteins in the 60-70 kDa range, necessitating careful interpretation of signals in this molecular weight range .

• Loading controls: Include appropriate mitochondrial marker proteins (e.g., subunits of other respiratory complexes) as loading controls for Western blots.

How might ATP25 research inform studies of human mitochondrial diseases?

While ATP25 has been primarily studied in yeast, its function in maintaining mitochondrial ATP synthase assembly has potential implications for human mitochondrial disorders:

• Identification of human homologs: Computational approaches can identify potential human homologs of ATP25 that might serve similar functions in stabilizing mRNAs for ATP synthase components.

• Disease association studies: Examine whether mutations in human ATP25 homologs are associated with mitochondrial disorders characterized by ATP synthase deficiency.

• Therapeutic target potential: The dual function of ATP25 in mRNA stability and protein assembly suggests multiple potential intervention points for disorders involving ATP synthase dysfunction.

• Model system development: Develop mammalian cell models with mutations in ATP25 homologs to study effects on mitochondrial function and potential therapeutic approaches.

What advanced techniques could further elucidate ATP25 functional mechanisms?

Several cutting-edge approaches could provide deeper insights into ATP25 function:

• Cryo-electron microscopy: Determine the structure of ATP25 and its interactions with ATP9 mRNA and/or the Atp9p protein to understand the molecular basis of its dual function.

• RNA-protein interaction studies: Apply techniques such as CLIP-seq (crosslinking immunoprecipitation followed by sequencing) to identify precise RNA binding sites within the C-terminal domain of ATP25.

• Single-molecule fluorescence: Track the dynamics of ATP25-mediated assembly of Atp9p into the ATPase complex in real-time.

• In vitro reconstitution: Reconstitute ATP25 function with purified components to determine the minimal system required for ATP9 mRNA stabilization and Atp9p assembly.